非黑色素瘤皮肤癌的挽救性再程放疗:一项多中心分析
这项多中心真实世界研究回顾性收集了2006至2022年间五家高容量近距离治疗中心收治的58例头颈部非黑色素瘤皮肤癌复发患者,评估根治性挽救性再程放疗的结局。主要终点为局部控制,1年局部控制率为73.1%,3年降至41.7%;再照射病灶大小是唯一独立预后因素(每毫米HR 1.07,95%CI 1.04-1.11,p<0.001),7例(12.1%)报告≥3级不良事件。作者认为再程放疗对经过选择的老年小病灶、局限、不可手术复发患者可作为一种选择,但需前瞻性试验证实其安全性和疗效。
要点
- 58例头颈部非黑色素瘤皮肤癌复发患者接受再程放疗,91.4%为基底细胞癌,91.4%采用高剂量率近距离治疗。
- 1年局部控制率73.1%,3年降至41.7%;再照射病灶大小是唯一独立预后因素(每毫米HR 1.07,95%CI 1.04-1.11,p<0.001)。
- 7例(12.1%)报告≥3级不良事件;作者认为再程放疗对经过选择的老年小病灶、局限、不可手术复发患者可作为一种选择。
核心结论
- 再程放疗主要用于放射性复发基底细胞癌的近距离治疗,与高复发率相关,且治疗失败风险随再照射病灶尺寸增大而显著增加。
- 作者认为再程放疗对经过选择的老年小病灶、局限、不可手术的放疗后复发患者可作为一种选择,以实现局部控制或推迟全身治疗,但需前瞻性试验证实其安全性和疗效。
研究设计与样本
- 多中心真实世界研究,回顾性收集2006至2022年间五家高容量近距离治疗中心收治的接受再程放疗的非黑色素瘤皮肤癌患者数据,共58例,中位年龄78.4岁,复发部位均位于头颈部。
- 主要终点为局部控制,次要终点包括总生存、无进展生存和不良事件,采用Kaplan-Meier估计和Cox比例风险模型进行分析。
主要发现
- 91.4%为皮肤基底细胞癌,91.4%接受高剂量率近距离治疗;最常见部位为鼻部(36.2%)和外耳(18.9%)。
- 1年局部控制率为73.1%,3年降至41.7%。
- Cox分析显示再照射病灶大小是唯一独立预后因素(每毫米HR 1.07,95%CI 1.04-1.11,p<0.001)。
- 7例(12.1%)报告≥3级不良事件。
临床怎么用
- 作者认为再程放疗对经过选择的老年小病灶、局限、不可手术的放疗后复发患者可作为一种选择,以实现局部控制或推迟全身治疗。
局限性
- 原文为回顾性数据收集。
- 作者指出需前瞻性试验证实再程放疗的安全性和疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We conducted a multicentre real-world study to assess the outcomes of radical salvage re-irradiation for non-melanoma skin cancer (nMSC) recurrences following definitive or postoperative radiotherapy. MATERIALS AND METHODS: Data on patients treated between 2006 and 2022 with re-irradiation for nMSCs were retrospectively collected from five high-volume brachytherapy centers. The primary endpoint was local control (LC). Secondary endpoints included overall survival, progression-free survival, and adverse events (AEs). The Kaplan-Meier estimator and Cox Proportional-Hazards Model were utilised in the analysis. RESULTS: A total of 58 patients with a median age of 78.4 years with recurrences of previously irradiated nMSC in the head and neck region were included in the analysis. The majority had cutaneous basal cell carcinoma (BCC; 91.4%), and were irradiated with high-dose-rate brachytherapy (HDR-BT; 91.4%). The most common locations included the nasal region (36.2%) and external ear (18.9%). The 1-year LC was 73.1% and decreased to 41.7% at three years. The size of the re-irradiated lesion was the single independent prognostic factor in Cox analysis (per mm; HR 1.07; 95% CI 1.04-1.11; p < 0.001). Grade 3 or worse AEs were reported in 7 cases (12.1%). CONCLUSION: Re-irradiation for nMSCs, predominantly administered with brachytherapy for radiorecurrent BCC, is associated with high recurrence rates, and the risk of failure significantly increases with the size of the treated lesion. Re-irradiation could be an option for selected elderly patients with small, localised, inoperable recurrences after RT to achieve local control or defer systemic treatment; however, prospective trials are necessary to confirm its safety and efficacy.
引用
- Miszczyk M, Suleja A, Sobel S, et al. Salvage re-irradiation in non-melanoma skin cancers: A multicenter analysis. Radiother Oncol. 2023. PMID: 37806558. doi:10.1016/j.radonc.2023.109945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。